Personalized medicine has taken on a new meaning with the mapping of the human genome.
With a clearer understanding of each individual’s own genetic makeup, America’s Biopharmaceutical Companies are making groundbreaking innovations that deliver personalized medicines to patients. Personalized medicine is changing the course of treatment in a host of therapeutic areas – from oncology to cystic fibrosis; and holds incredible promise for diseases like Alzheimer’s. The completion of the Human Genome Project has catalyzed a new era of medicine, where scientific advances once unthinkable are today becoming a reality.
As part of the GOBOLDLY campaign, PhRMA is continuing our national dialogue series by discussing what genomics means in The New Era of Medicine with “Sequencing the Genome: Examining Modern Medicine” today, April 26th in partnership with The Atlantic. Over 40 percent of new medicines in development have the potential to be personalized medicines, and this event takes a deep dive into advances in genomic research and innovation, opportunities and challenges and what the future holds.
The program will be streamed live from 8:30 - 10:45 am ET, and those interested can join the conversation on Twitter with @PhRMA and #GoBoldy.
To learn more about the positive impact of the work being done by America’s biopharmaceutical companies, visit www.innovation.org.
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
Bayh-Dole: The fuel for America’s innovation engine
ICYMI: Biopharmaceutical companies in America hit new investment milestone
World Sickle Cell Day: Recognizing the promise of gene therapy
America's cancer research progress is real and worth protecting
A new era in genomics
GoBoldly
New Era of Medicine
Research and Development
A new era in genomics
A new era in genomics